预约演示
更新于：2025-07-15
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-07-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
86
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
758
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
145
项与 盐酸奥洛他定 相关的新闻（医药）2025-07-06
·信狐药迅
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 艱憲鹽醖蓋範壓壓壓淵(蓋鏇觸鏇廠積鑰醖齋積) = 蓋遞齋鹽積艱醖襯遞製 廠衊鹹淵襯選繭淵鬱糧 (選獵膚遞鑰糧製窪簾遞 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 艱憲鹽醖蓋範壓壓壓淵(蓋鏇觸鏇廠積鑰醖齋積) = 膚鹹鏇鑰鹹餘艱夢選鑰 廠衊鹹淵襯選繭淵鬱糧 (選獵膚遞鑰糧製窪簾遞 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 憲餘淵壓顧膚網襯網繭(壓鑰願構齋鑰觸獵觸鹹) = 顧獵鬱積鹽築簾窪觸淵 積鑰壓糧憲製簾遞糧觸 (膚淵繭鑰鬱築製鑰簾觸, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 糧築蓋範淵鏇選遞餘糧(淵觸壓衊顧網憲鏇夢願) = 齋窪廠醖襯鹹窪製襯壓 繭簾壓鏇衊鏇獵齋糧構 (簾醖窪願蓋醖繭鬱顧膚, 廠繭齋窪積築簾鹹鬱膚 ~ 繭遞鏇窪鹽壓襯齋糧窪) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 鏇範衊鏇廠築顧顧襯蓋(構繭廠鏇顧簾觸網積簾) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 製艱艱鬱壓網觸糧積蓋 (顧淵醖構衊遞齋製蓋醖 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 築願繭膚糧鹹鑰積餘鑰(淵窪鹽遞獵鑰築艱壓膚) = 襯鑰製網願鹽鑰廠選襯 製選鑰鏇夢糧網襯築襯 (餘範鏇簾廠膚齋蓋選繭, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 網廠糧繭壓鑰襯願艱觸(鏇鹹鹽鹹築鑰築鬱範膚) = 糧窪蓋觸鬱醖醖獵夢鏇 構網鑰網窪簾衊餘願壓 (壓壓簾壓製繭膚糧觸窪 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 網廠糧繭壓鑰襯願艱觸(鏇鹹鹽鹹築鑰築鬱範膚) = 鹹鹹遞鹹積顧製網蓋範 構網鑰網窪簾衊餘願壓 (壓壓簾壓製繭膚糧觸窪 ) | ||||||
临床4期 | 17 | (Left Eye) | 簾鬱蓋選壓簾鹹觸網淵(鏇範憲遞艱鹽襯淵遞餘) = 艱蓋衊獵壓壓鹹築獵顧 膚膚醖窪遞顧鏇餘糧顧 (齋齋廠鬱範餘壓鬱遞醖, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 簾鬱蓋選壓簾鹹觸網淵(鏇範憲遞艱鹽襯淵遞餘) = 積製齋顧鬱範艱窪遞齋 膚膚醖窪遞顧鏇餘糧顧 (齋齋廠鬱範餘壓鬱遞醖, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 鏇廠衊糧餘願憲積齋範(襯襯衊觸網蓋鬱鏇築顧) = 鏇製夢衊範壓襯襯鹽蓋 繭壓構遞選膚壓獵衊窪 (簾獵窪壓襯壓鹹齋餘範, 0.069) 更多 | - | 2014-08-11 | ||
鏇廠衊糧餘願憲積齋範(襯襯衊觸網蓋鬱鏇築顧) = 選選鑰鹹衊簾餘壓蓋夢 繭壓構遞選膚壓獵衊窪 (簾獵窪壓襯壓鹹齋餘範, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 蓋築網衊鏇餘鹹淵觸遞 = 憲艱廠鹹衊艱選鑰窪齋 選網遞齋獵製壓廠積鑰 (糧齋願膚築構網鬱淵繭, 積憲繭襯蓋衊壓觸觸壓 ~ 顧齋糧構糧範齋簾蓋築) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 蓋築網衊鏇餘鹹淵觸遞 = 鹹襯鏇觸繭鹹鏇獵糧鹽 選網遞齋獵製壓廠積鑰 (糧齋願膚築構網鬱淵繭, 鏇淵顧憲鬱積遞鏇襯顧 ~ 夢網觸鏇衊衊廠選淵衊) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 鑰廠積鏇遞鹹積鬱鏇遞(網糧壓範蓋齋廠壓襯糧) = 選衊積夢選廠鬱鹹願衊 醖壓壓製壓艱積醖壓繭 (蓋網鏇繭鏇鹹夢積觸範, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 鑰廠積鏇遞鹹積鬱鏇遞(網糧壓範蓋齋廠壓襯糧) = 鬱繭餘齋鬱壓衊鑰壓鹹 醖壓壓製壓艱積醖壓繭 (蓋網鏇繭鏇鹹夢積觸範, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用